Stock Analysis

NetScientific Full Year 2023 Earnings: UK£0.11 loss per share (vs UK£0.14 loss in FY 2022)

AIM:EMVC

NetScientific (LON:NSCI) Full Year 2023 Results

Key Financial Results

  • Net loss: UK£2.64m (loss narrowed by 15% from FY 2022).
  • UK£0.11 loss per share (improved from UK£0.14 loss in FY 2022).
AIM:NSCI Earnings and Revenue Growth June 19th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

NetScientific Earnings Insights

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom.

Performance of the British Medical Equipment industry.

The company's shares are up 6.7% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with NetScientific (at least 1 which shouldn't be ignored), and understanding these should be part of your investment process.

Valuation is complex, but we're here to simplify it.

Discover if EMV Capital might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.